funding from IMI, EFPIA
partners in Europe and the US
RADAR-AD (Remote Assessment of Disease And Relapse – Alzheimer’s Disease) is jointly led by King’s College London and Janssen Pharmaceutica, with funding from the Innovative Medicines Initiative (IMI) and in-kind contributions from industrial partners.
It is RADAR-AD’s vision to radically improve the assessment of Alzheimer’s disease (AD) and the care for people living with Alzheimer’s. We aim to do so by exploring how mobile technologies – such as smart phones, wearables and home-based sensors – can be used to measure disability progression associated with AD.
These technologies allow us to sensitively measure cognitive and functional decline in people with AD. However, it is currently unclear how we can use this potential to improve AD assessment and care – which is exactly what we are trying find out.
In this project, we aim to investigate how mobile technologies can improve our understanding of AD. For example, these techniques might help to detect AD earlier in people with cognitive decline. Mobile technology also allows for a more personalized approach to AD treatment and care, so that people with this disease can live independently for longer. In addition, we also aim to identify “digital biomarkers” (electronic signals that give information about a person’s health status) for AD. This creates new perspectives for the development of treatments against this progressive and debilitating condition.
Lygature in RADAR-AD
Providing multi-disciplinary partnership management, communications, patient engagement and regulatory expertise
- Program management. Lygature is a member of the project’s Management Team. Together with partner Janssen, Lygature coordinates this large and multi-disciplinary program on a day-to-day basis. Activities include monitoring the effective execution of the work plan and its progress, creation and alignment of work processes, resource management and internal communication.
- Communication and Dissemination. Lygature leads the Communication and Dissemination work package in RADAR-AD. Lygature provides the backbone for knowledge sharing and is responsible for the design and development of the public website, as well as a visual identity for the project. Our goal is to raise public and scientific awareness of remote assessment of disease and relapse in early Alzheimer’s disease and to disseminate our results to the scientific community and the general public in the most efficient way. We do this through regular communication on our website, social media channels and public outreach on scientific and non-scientific events through targeted campaigns and presentations.
- Communication with regulatory authorities, patient associations, payers and ethics boards. The project is also exploring new territory regarding the rules, regulations, patient needs and ethical challenges associated with mobile technology and health. In RADAR-AD, we have the expertise on board to address these often complex conundrums. For example, the Dutch Medicines Evaluation Board brings their regulatory knowledge to the table, and Alzheimer Europe ensures that the patient voice is being heard. As Lygature, we contribute by functioning as an independent broker between these different stakeholders. We stimulate, organize, facilitate conversations between the consortium and external parties, such as regulators, patient associations, and ethics specialists.
The contribution made by Lygature to RADAR-AD is an example of how cross-disciplinary expertise built up during major projects can be applied in new areas.
Lygature together with
King’s College London, VU University Medical Centre, The Hyve, University of Oxford, Karolinska Institutet, College ter Beoordeling van Geneesmiddelen / Medical Evaluation Board, Fraunhofer Institute for Algorithms and Scientific Computing, Alzheimer Europe, Janssen Pharmaceutica NV, Takeda Development Centre Europe Ltd, Novartis Pharma AG, Eli Lilly, Software AG, Centre for Research and Technology Hellas, Altoida AG
RADAR-AD receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806999. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. See www.imi.europa.eu for more details.
RADAR-AD researchers: Interview series “Behind-the-scenes”
To show the variety of work we do in RADAR-AD, the following news items are dedicated to several RADAR-AD researchers. They share the work they do for the project, what excites and challenges them the most, especially at times of the present COVID-19 pandemic, and how they see the impact of our project for the wider field of Alzheimer’s research.
Read the full interviews here.
Consultation meeting at EMA: Joint effort of the RADAR-CNS and RADAR-AD consortium members
On the 4th of February 2020, RADAR-CNS and RADAR-AD project members visited the European Medicines Agency (EMA) in Amsterdam, The Netherlands for a consultation meeting with the Innovation Task Force (ITF). The objective of EMA’s ITF briefing meetings is to set the stage for scientific and regulatory discussions that relate to the development of new medicinal products and technologies. The purpose of this meeting was to inform the IMI on the both RADAR projects, and to exchange thoughts on a number of items that are associated with remote measuring technologies and the development of digital endpoints.
New Research Consortium Aims to Measure Progression of Alzheimer’s Disease Through Use of Digital Technologies
“A new international consortium of academic and industrial leaders in the field of Alzheimer’s Disease (AD) is pleased to announce the launch of “RADAR-AD” (Remote Assessment of Disease And Relapse – Alzheimer’s Disease). The collaborative research program aims to develop technologies that remotely identify and measure “digital biomarkers” to assess the progression of early AD. RADAR-AD is a three-and-a-half-year public-private partnership, sponsored by the Innovative Medicines Initiative (IMI), and led by King’s College London and Janssen Pharmaceutica N.V.